June 2012 | Oncology & Biotech News

August 20, 2012

Trials underway in gastrointestinal, oral, head and neck, and brain cancer intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the oncology community.

August 20, 2012

The nonsteroidal anti-inflammatory drug naproxen significantly decreases the incidence, severity, and duration of pegfilgrastim-induced bone pain in patients diagnosed with a nonmyeloid cancer.

July 19, 2012

The long-standing debate about postmenopausal hormones and breast cancer gained more evidence to support an increased cancer risk.

July 18, 2012

A modified intraperitoneal (IP) regimen for advanced ovarian cancer demonstrated feasibility, tolerability, and evidence of effectiveness, results of a small pilot study suggest.

July 16, 2012

Health plans continue to seek methods to curtail cancer costs.

July 13, 2012

Many contemporary issues in the US healthcare system affect clinicians in all areas of medicine. Some issues are even more specific to the field of gynecologic oncology.

July 12, 2012

Field-directed treatment with the investigational topical agent ingenol mebutate has been shown to be effective for actinic keratoses on the head and body.

July 09, 2012

Recent clinical and economic studies have suggested that ovarian cancer regimens containing bevacizumab could fall within the boundaries of cost-effectiveness, at least for some patients.

July 06, 2012

Three-fourths of patients with advanced hepatocellular carcinoma associated with hepatitis C infection achieved disease control with antibody therapy directed at a T-cell antigen.

July 06, 2012

For nearly 40 years, the University of Chicago Comprehensive Cancer Center has enjoyed a reputation for excellence and innovation.

July 05, 2012

The cancer proliferation marker Ki-67 decreased significantly in men who took high-dose vitamin D in the weeks leading up to radical prostatectomy for localized prostate cancer.

July 04, 2012

Women who have been previously treated for early-stage breast cancer are much less likely to complain of hot flashes if they remain within 10% of their prediagnosis weight.

July 03, 2012

The administration of nab-paclitaxel plus carboplatin results in a significantly higher ORR than conventional solvent-based paclitaxel with carboplatin in previously untreated patients with advanced NSCLC.

July 02, 2012

Breast cancer survival improved significantly in patients who increased consumption of cruciferous vegetables following diagnosis, a study of Chinese women showed.

July 02, 2012

Four studies reflected the growing interest in-and the volume of evidence for-using the diabetes drug metformin as a potential cancer therapy.

June 28, 2012

More than a third of cancer survivors report ongoing symptoms of posttraumatic stress disorder several years after being diagnosed with cancer.

June 25, 2012

Unexpected target mutations likely doomed a proven therapeutic approach to lung cancer in a test against glioblastoma.

June 24, 2012

The addition of bevacizumab to first-line carboplatin-paclitaxel did not prolong survival in Medicare recipients with advanced non–small cell lung cancer.

June 23, 2012

Young women who have recently used DMPA for at least 1 year have more than twice the risk of invasive breast cancer as young women who do not report recent use of the injectable contraceptive.

June 22, 2012

Cancer drugs once deemed too toxic for humans have earned a second chance at therapeutic utility, in part because of a reversal in the usual progression of medical research.

June 22, 2012

In the past few years the pace of discovery of effective immunotherapies has accelerated as a consequence of better chemistry and understanding of immune biology.